LIVE WEBINAR: Friday, December 4, 2020, 12:00 PM – 1:30 PM Pacific Time (3:00 PM – 4:30 PM Eastern Time)

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Chronic Lymphocytic Leukemia (Part 2 of a 4-Part Series)


Matthew S Davids, MD, MMSc
Associate Professor of Medicine, Harvard Medical School
Director, DFCI Lymphoma BioBank
Associate Director, CLL Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Kerry Rogers, MD
Assistant Professor in the Division of Hematology
The Ohio State University
Columbus, Ohio

Tanya Siddiqi, MD
Associate Professor
Director, Chronic Lymphocytic Leukemia Program
Department of Hematology and Hematopoietic Cell Transplantation
City of Hope National Medical Center
Duarte, California

Professor Dr Stephan Stilgenbauer
Ulm University, Ulm, Germany
Saarland University
Homburg, Germany

William G Wierda, MD, PhD
DB Lane Cancer Research Distinguished Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company.

Friday, December 4, 2020
12:00 PM – 1:30 PM PT (3:00 PM – 4:30 PM ET)
Live CME-accredited webinar

Topics to Be Discussed

  • Treatment for Younger, Fit Patients with Chronic Lymphocytic Leukemia (CLL)
  • Up-Front Management of CLL in Older Patients or Those with Comorbidities
  • Optimal Management of Adverse Events Associated with BTK and Bcl-2 Inhibitors
  • Selection and Sequencing of Therapies for Relapsed/Refractory CLL
  • Novel Strategies Under Investigation for CLL
A detailed agenda will be provided by November.

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

  • Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering clinical presentation, biomarker profile, coexisting medical conditions and patient preferences.
  • Discuss available Phase III data demonstrating the superior efficacy and safety of BTK (Bruton tyrosine kinase) inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to discern how this strategy can be optimally integrated into nonresearch treatment.
  • Appraise the Phase III data supporting the recent FDA approval of acalabrutinib for newly diagnosed or previously treated CLL, and identify patients for whom treatment with this agent may be appropriate.
  • Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how to appropriately integrate this regimen into current treatment decision-making.
  • Analyze how age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) CLL.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies employed in the management of CLL.
  • Recognize the biologic rationale for, available research evidence with and ongoing clinical trials evaluating the use of chemotherapy-free combinations in the management of newly diagnosed and progressive CLL, and identify patients who may be suitable candidates for these approaches outside or as part of research studies.
  • Develop an understanding of the biologic rationale for chimeric antigen receptor T-cell therapy for patients with R/R CLL, appreciate available efficacy and safety data with this novel approach and consider its potential clinical role.
  • Recall available and emerging data with other investigational agents, combinations and strategies currently under investigation for CLL and, where applicable, refer eligible patients for trial participation.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company.